Seth Berkley

Learn More
Prompted by the 20th anniversary of the 1993 World Development Report, a Lancet Commission revisited the case for investment in health and developed a new investment framework to achieve dramatic health gains by 2035. The Commission's report has four key messages, each accompanied by opportunities for action by national governments of low-income and(More)
It seems appropriate that The Lancet should launch the Every Newborn Series in the year of the 40th anniversary of the Expanded Programme for Immunization, and of the 20th anniversary of the fi rst publication showing evidence that antiviral treatment can prevent mother-to-child transmission of HIV. Not only have these factors had a positive eff ect on(More)
In recent years, venture capital approaches have delivered impressive results in identifying and funding promising health discoveries and bringing them to market. This success has inspired public sector experiments with "social venture capital" approaches to address the dearth of affordable treatment and prevention for diseases of the developing world.(More)
A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine(More)
1 Mackenbach J, McKee M. Successes and failures of health policy in Europe: four decades of divergent trends and converging challenges. Milton Keynes: Open University Press, 2013. 2 WHO. European health for all database. (accessed Feb 14, 2013). 3 WHO. Health 2020: a European policy framework supporting action across government(More)
To the editor: As CEO and president of the International AIDS Vaccine Initiative (IAVI; New York), I am writing to protest against a news brief “HIV vaccine controversy” in your March issue1, which I regard as both tendentious and inaccurate. First, it is impossible for a phase 1 vaccine trial—like the one of the AIDS vaccine candidate tgAAC09 that IAVI(More)
Vaccines have proved to be one of the most powerful and effective ways of reducing disease. However, if we are to maximize their impact on global health, then we need to develop new vaccines for additional diseases as well as to improve their supply and delivery, particularly in developing countries.